EBS News and Press, Emergent Biosolutions Inc. From 03/23/22

Emergent BioSolutions (NYSE:EBS) appointed Zsolt Harsanyi, independent director, as chairman of the board. EBS decided to eliminate the role of executive chairman in favor of an independent, non-executive chairman and will no longer require the role of lead independent director. Ronald R...

Zsolt Harsanyi, Ph.D. Appointed Chairman of the Board Keith Katkin Appointed to the Board Eliminates Role of Executive Chairman Appoints New Chairs of Audit, Strategic Operations, and Scientific Review Committees GAITHERSBURG, Md., March 23, 2022 (GLOBE NEWSWIRE) -- Emer...

Emergent BioSolutions (NYSE:EBS) dosed the first person in a phase 1 trial of stabilized isoamyl nitrite (SIAN) to treat known or suspected acute cyanide poisoning. Under an existing multi-year contract with the Biomedical Advanced Research and Development Authority (BARDA), and in collaborat...

GAITHERSBURG, Md., March 11, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has dosed the first participant in its Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of stabilized isoamyl nitrite (SIAN), a trea...

PBE is neither suitable for income seekers, nor for long term investors. Despite being a Genomic revolution fund, it lacks focus, and invested heavily on large cap diverse biotechnology companies. Better biotechnology ETFs of similar nature are available in the market. For f...

The following slide deck was published by Emergent BioSolutions Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Emergent BioSolutions Inc. 2021 Q4 - Results - Earnings Call Presentation

Emergent BioSolutions (NYSE: EBS) ended the week on a down note. Shares of the company closed 6.2% lower on Friday after it provided its fourth-quarter update following the market close on Thursday. Is the stock a buy on the dip? There certainly were some positive takeaways for ...

Shares of Emergent BioSolutions (NYSE: EBS) were slipping 3.8% as of 11:38 a.m. ET on Friday and fell as much as 7.7% earlier in the day. The decline came following the company's fourth-quarter update on Thursday after the market close. Emergent reported fourth-quarter revenue o...

Image source: The Motley Fool. Emergent BioSolutions (NYSE: EBS) Q4 2021 Earnings Call Feb 24, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Emergent BioSolutions (EBS) Q4 2021 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q4 2021 Earnings Conference Call February 24, 2022, 05:00 PM ET Company Participants Bob Burrows - IR Officer Bob Kramer - President and CEO Rich Lindahl - CFO Adam Havey - Chief Operating Officer Conference Call Participants Brandon Folkes - Cantor Fitzgerald...